<?xml version="1.0" encoding="UTF-8"?>
<p id="p0035">Bio-prospecting is to a great extent anchored on indigenous knowledge systems and the institutions of collective action [
 <xref rid="bib11" ref-type="bibr">11</xref>]. In most cases, the isolation of active pharmacological agents in bioprospection is patented and commercialised. However, commercialisation and patenting are often guided by policy discourses that conflict with existing customary rights on access, use and control of medicinal plant resources. Literature suggest that bioprospecting and subsequent commercialisation of medicinal plants has mixed outcomes in Africa and other parts of the world [
 <xref rid="bib14" ref-type="bibr">14</xref>, 
 <xref rid="bib15" ref-type="bibr">15</xref>]. For example, the increased vulnerability to extinction of a number of endemic medicinal flora
 <italic>,</italic> such as African ginger 
 <italic>(Hypoxis hemerocallidea) in</italic> South Africa is attributed to high demand, destructive harvesting practices and inherent slow growth of such species [
 <xref rid="bib15" ref-type="bibr">15</xref>, 
 <xref rid="bib16" ref-type="bibr">16</xref>].
</p>
